Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Apr 10.

Published in final edited form as: Small. 2021 Mar 7;17(14):e2005993. doi: 10.1002/smll.202005993

Fig. 1 — Synthesis of activated Pt drugs for the purpose of encapsulation by silicasomes. (A) Pt drugs are coordination compounds, with the basic structural composition of cis-[PtA₂X₂]. A₂, i.e., two monodentate or one bidentate ligand with nitrogen donor atoms; X₂: two monodentate or one bidentate anionic ligand(s). Representative Pt drugs studied in this project include oxaliplatin, cisplatin and Pt(en)Cl₂. (B) Pt drugs in aqueous solution exist as equilibration species that can be depicted as “neutral” or “cationic”; the cationic variant is pharmaceutically active and capable of providing DNA cross linking. (C) Synthesis of cationic and active version of Pt drugs. This resulted in DACHPt (for oxaliplatin), DAPt (for cisplatin) and EDAPt (for Pt(en)Cl₂), respectively. The yield of these reactions is high, i.e. ~95%.

Fig. 1 — Synthesis of activated Pt drugs for the purpose of encapsulation by silicasomes. (A) Pt drugs are coordination compounds, with the basic structural composition of cis-[PtA₂X₂]. A₂, i.e., two monodentate or one bidentate ligand with nitrogen donor atoms; X₂: two monodentate or one bidentate anionic ligand(s). Representative Pt drugs studied in this project include oxaliplatin, cisplatin and Pt(en)Cl₂. (B) Pt drugs in aqueous solution exist as equilibration species that can be depicted as “neutral” or “cationic”; the cationic variant is pharmaceutically active and capable of providing DNA cross linking. (C) Synthesis of cationic and active version of Pt drugs. This resulted in DACHPt (for oxaliplatin), DAPt (for cisplatin) and EDAPt (for Pt(en)Cl₂), respectively. The yield of these reactions is high, i.e. ~95%.